Skip to main content
SpringerLink
Log in

Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Tegaserod is a new partial agonist of serotonin 5-HT4 receptors specifically developed for the treatment of nondiarrhoeal forms of irritable bowel syndrome (IBS). Among its various effects is the stimulation of the peristaltic reflex with its promotility action appearing to affect the whole length of the gastrointestinal tract. Tegaserod has been assessed in a number of international multicentre trials and its use leads to an improvement in abdominal pain and bowel dysfunction as well as global well-being, at the expense of remarkably few adverse effects. It is noteworthy that it also appears to improve bloating, a benefit that has not been previously reported for a medication used in IBS. The optimal dose is 6mg twice daily and the advantage of tegaserod over placebo in different trials varies from 5–20% with the number needed to treat ranging from 5–15 depending on the time at which this effect is calculated during the course of a trial. Recent experience with other drugs acting on 5-HT receptors has focused attention on possible safety issues such as prolongation of the QTc interval on the electrocardiogram and ischaemic colitis. However, data from efficacy trials and studies specifically designed to address the safety of tegaserod have not revealed any evidence of cardiotoxicity or the potential for causing ischaemic colitis. Furthermore, investigation of possible interactions with other drugs such as warfarin or the oral contraceptive have not resulted in any prescribing restrictions. Inappropriate prescription of tegaserod to a subgroup of IBS patients for which the drug was not designed, does not appear to have any serious consequences. Most of the efficacy data on tegaserod has been accumulated in females, simply as a result of the failure to recruit adequate numbers of males or restriction of trials to females. There is therefore insufficient information to assess whether there might be any potential gender differences in responsiveness. For this reason, the drug is currently only licensed for use in females.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100(4): 998–1005

    PubMed  CAS  Google Scholar 

  2. Switz DM. What the gastroenterologist does all day: a survey of a state society’s practice. Gastroenterology 1976; 70(6): 1048–50

    PubMed  CAS  Google Scholar 

  3. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123(6): 2108–31

    Article  PubMed  Google Scholar 

  4. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38(9): 1569–80

    Article  PubMed  CAS  Google Scholar 

  5. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2(6138): 653–4

    Article  PubMed  CAS  Google Scholar 

  6. Thompson WG, Creed FH, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 75–91

    Google Scholar 

  7. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45Suppl. 2: II43–7

    Article  PubMed  Google Scholar 

  8. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002; 122(6): 1701–14

    Article  PubMed  Google Scholar 

  9. Talley NJ, Zinsmeister AR, Melton III LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142(1): 76–83

    PubMed  CAS  Google Scholar 

  10. Hahn B, Watson M, Yan S, et al. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998; 43(12): 2715–8

    Article  PubMed  CAS  Google Scholar 

  11. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001; 19(6): 643–53

    Article  PubMed  CAS  Google Scholar 

  12. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95(10): 2698–709

    PubMed  CAS  Google Scholar 

  13. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358(9298): 2061–8

    Article  PubMed  CAS  Google Scholar 

  14. Bach T, Syversveen T, Kvingedal AM, et al. 5-HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol 2001; 363(2): 146–60

    Article  PubMed  CAS  Google Scholar 

  15. Corsetti M, Tack J. Tegaserod: a new 5-HT4 agonist in the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2002; 3: 1211–8

    Article  PubMed  CAS  Google Scholar 

  16. Tonini M, Messori E, Franceschetti GP, et al. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle. Br J Pharmacol 1994; 113(1): 1–2

    Article  PubMed  CAS  Google Scholar 

  17. Pata C, Erdal ME, Derici E, et al. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2002; 97(7): 1780–4

    Article  PubMed  CAS  Google Scholar 

  18. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123(2): 425–32

    Article  PubMed  CAS  Google Scholar 

  19. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95(1): 232–41

    PubMed  CAS  Google Scholar 

  20. Northcutt A, Mangel AW, Hamm LR, et al. Persistent placebo response during a year long controlled trial of IBS treatment [abstract no. 3243]. Gastroenterology 2001; 120(5) Suppl. 1: A640

    Google Scholar 

  21. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107(5A): 91S–7S

    Article  PubMed  CAS  Google Scholar 

  22. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45Suppl. 2: II69–77

    Article  Google Scholar 

  23. Talley NJ. Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992; 6(3): 273–89

    Article  PubMed  CAS  Google Scholar 

  24. Kamm MA. Review article: the complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16(3): 343–51

    Article  PubMed  CAS  Google Scholar 

  25. Bearcroft CP, Andre EA, Farthing MJ. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11(6): 1109–14

    Article  PubMed  CAS  Google Scholar 

  26. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000; 14(6): 775–82

    Article  PubMed  CAS  Google Scholar 

  27. Kozlowski CM, Green A, Grundy D, et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distension induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46(4): 474–80

    Article  PubMed  CAS  Google Scholar 

  28. Novartis Pharmaceuticals, 2002 (Data on file)

  29. Pfannkuche H, Bhul T, Gamse R, et al. The properties of a new prokinetically active drug SDZ HTF919. Neurogastroenterol Motil 1995; 7

    Google Scholar 

  30. Clark RB, Knoll BJ, Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 1999; 20(7): 279–86

    Article  PubMed  CAS  Google Scholar 

  31. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15(3): 277–89

    Article  PubMed  CAS  Google Scholar 

  32. Fidelholtz J, Smith W, Rawls J, et al. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol 2002; 97(5): 1176–81

    Article  PubMed  CAS  Google Scholar 

  33. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115(2): 370–80

    Article  PubMed  CAS  Google Scholar 

  34. Stoner M, Arcuni J, Lee J, et al. A selective 5-HT4 receptor agonist induces cAMP mediated Cl- efflux from rat colonocytes [abstract no. G2827]. Gastroenterology 1999 Apr; 116(4) Pt 2: A648

    Google Scholar 

  35. Fioramonti J, Million M, Bueno L. Investigations on a 5-HT4 agonist (SDZ HTF919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying [abstract no. G3103]. Gastroenterology 1998 Apr; 114(4) Pt 2: A752

    Article  Google Scholar 

  36. Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14(3): 221–7

    Article  PubMed  CAS  Google Scholar 

  37. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17(4): 577–85

    Article  PubMed  CAS  Google Scholar 

  38. Drici MD, Ebert SN, Wang WX, et al. Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart. J Cardiovasc Pharmacol 1999; 34(1): 82–8

    Article  PubMed  CAS  Google Scholar 

  39. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet 2002; 41(13): 1021–42

    Article  PubMed  CAS  Google Scholar 

  40. Appel-Dingemanse S, Hirschberg Y, Osborne S, et al. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur J Clin Pharmacol 2001; 56(12): 889–91

    Article  PubMed  CAS  Google Scholar 

  41. Ledford P, On N, Ligueros-Saylan M, et al. Tegaserod does not significantly affect the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects [abstract no. 5445]. Gastroenterology 2000; 118(4) Suppl. 2

    Google Scholar 

  42. Zhou H, Walter Y, Hubert M, et al. Tegaserod (HTF919) does not decrease the effectiveness of an oral contraceptive when co-administered to healthy female subjects [abstract no. 1024]. Gastroenterology 2000; 118(4) Suppl. 2

    Google Scholar 

  43. Zhou H, Horowitz A, Ledford PC, et al. The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. J Clin Pharmacol 2001; 41(10): 1131–9

    Article  PubMed  CAS  Google Scholar 

  44. Zhou H, Khalilieh S, Svendsen K, et al. Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects. J Clin Pharmacol 2001; 41(9): 987–93

    Article  PubMed  CAS  Google Scholar 

  45. Lefkowitz M, Ruegg P, Shi Y, et al. Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF919 [abstract no. G4462]. Gastroenterology 1999 Apr; 116(4) Pt 2: A1027

    Google Scholar 

  46. Hamiling J, Bang C, Tarpila S. Titration regimen indicates partial 5-HT4 agonist HFT919 improves symptoms of constipation predominant irritable bowel syndrome (C-IBS). Digestion 1998; 59Suppl. 3: 735

    Google Scholar 

  47. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97(11 Suppl.): S7–26

    PubMed  Google Scholar 

  48. Lefkowitz M, Shi Y, Schmitt C, et al. The 5HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalises altered bowel function in irritable bowel syndrome. Am J Gastroenterol 1999; 94: 2676

    Google Scholar 

  49. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15(10): 1655–66

    Article  PubMed  CAS  Google Scholar 

  50. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16(11): 1877–88

    Article  PubMed  CAS  Google Scholar 

  51. Kellow J, Lee O, Chang F, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52(5): 671–6

    Article  PubMed  CAS  Google Scholar 

  52. Hawkey CJ. Irritable bowel syndrome clinical trial design: future needs. Am J Med 1999; 107(5A): 98S–102S

    Article  PubMed  CAS  Google Scholar 

  53. Lefkowitz M, Ruegg P, Shi Y, et al. Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserod. Digestion 1998; 59: 735

    Google Scholar 

  54. Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17(8): 997–1005

    Article  PubMed  CAS  Google Scholar 

  55. Tougas G, Snape Jr WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16(10): 1701–8

    Article  PubMed  CAS  Google Scholar 

  56. Dobrilla G, Imbimbo BP, Piazzi L, et al. Long-term treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut 1990; 31(3): 355–8

    Article  PubMed  CAS  Google Scholar 

  57. Gilbody JS, Fletcher CP, Hughes IW, et al. Comparison of two different formulations of mebeverine hydrochloride in irritable bowel syndrome. Int J Clin Pract 2000; 54(7): 461–4

    PubMed  CAS  Google Scholar 

  58. Morganroth J, Ruegg PC, Dunger-Baldauf C, et al. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002; 97(9): 2321–7

    Article  PubMed  CAS  Google Scholar 

  59. Jones BW, Moore DJ, Robinson SM, et al. A systematic review of tegaserod for the treatment of irritable bowel syndrome. J Clin Pharm Ther 2002; 27(5): 343–52

    Article  PubMed  CAS  Google Scholar 

  60. Schoenfeld P, Chey W, Drossman DA, et al. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomised controlled trials [abstract no. T1486]. Gastroenterology 2002 Apr; 122(4): A465

    Google Scholar 

  61. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118(3): 463–8

    Article  PubMed  CAS  Google Scholar 

  62. Whorwell PJ, Krumbolz S, Muller-Lissner SA, et al. Tegaserod has a favourable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome. Gastroenterology 2000, 118

    Google Scholar 

Download references

Acknowledgments

Dr Whorwell has acted as an advisor to a number of pharmaceutical companies including Novartis for which he has received remuneration. Dr Lea is currently in receipt of an educational grant from Novartis Pharmaceuticals.

Author information

Authors and Affiliations

  1. Medical Academic Department, Education and Research Centre, South Manchester University Hospitals, Wythenshawe, Manchester, M23 2LT, United Kingdom

    Richard Lea &  Peter J. Whorwell

Authors
  1. Richard Lea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Whorwell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Whorwell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lea, R., Whorwell, P.J. Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome. Drug-Safety 27, 229–242 (2004). https://doi.org/10.2165/00002018-200427040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427040-00002

Keywords

Search

Navigation